You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

ERVEBO Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: ERVEBO
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for ERVEBO
Recent Clinical Trials for ERVEBO

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Institute of Tropical Medicine, BelgiumPhase 3
Institut National pour la Recherche Biomedicale (INRB)Phase 3
Agence Nationale de Sécurité Sanitaire de Guinée (ANSS)Phase 2

See all ERVEBO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ERVEBO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ERVEBO Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ERVEBO Derived from Patent Text Search

No patents found based on company disclosures

ERVEBO Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for the Biologic Drug: ERVEBO

Introduction

The development and market trajectory of ERVEBO, the first officially licensed vaccine for Ebola, is a complex and multifaceted story. This article delves into the market dynamics, financial aspects, and the broader context that has shaped the journey of ERVEBO from its inception to its current status.

Historical Context and Development

ERVEBO, also known as rVSV-ZEBOV (Ebola Zaire Vaccine), has a 20-year history that began at Canada’s National Microbiology Laboratory in Winnipeg, Manitoba. The vaccine was later licensed by BioProtection Systems Inc. (now Lumos Pharma) and underwent early manufacturing at IDT Biologika GmbH in Germany. The development process was significantly accelerated during the West African Ebola crisis in 2014[1].

Market Failure and Public Health Need

The development of ERVEBO highlights a critical issue in the pharmaceutical industry: the market failure for neglected tropical diseases. Ebola, like other diseases prevalent in developing countries, lacks commercial appeal due to the limited financial returns. This was a significant barrier until the global health security concerns raised during the 2014 outbreak[1].

Funding and Government Support

The financial trajectory of ERVEBO was heavily influenced by government funding and contracts. The U.S. government provided substantial funds for bioterrorism contracts, which were a key draw for companies involved in the vaccine's development. For instance, the U.S. government's funding for bioterrorism contracts was a significant motivator for BioProtection Systems Inc.[1].

Regulatory Approvals and Prequalification

A crucial milestone for ERVEBO was its regulatory approvals. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in December 2019 and received prequalification status from the World Health Organization (WHO) in November 2019. This prequalification allows ERVEBO to be procured and purchased by the UN and other global health entities, facilitating its inclusion in a global Ebola vaccines stockpile[4].

Global Health Response and Funding

The global response to Ebola outbreaks, particularly in the Democratic Republic of the Congo (DRC), has been financially significant. The U.S. has been the largest donor, providing over $266 million since August 2018 for response activities in the DRC and surrounding countries. This funding has been crucial for the deployment and administration of ERVEBO[2].

Market Impact and Demand

The demand for ERVEBO is driven by public health needs rather than traditional market forces. The vaccine's inclusion in lists of critical infectious diseases by the WHO and Gavi, The Vaccine Alliance, underscores its importance. The ongoing need for Ebola vaccination, especially in regions prone to outbreaks, ensures a steady demand for the vaccine[1][2].

Financial Trajectory

The financial trajectory of ERVEBO is intertwined with the broader biological drugs market. This market is experiencing robust growth, driven by research and development activities, increasing prevalence of chronic diseases, and growing demand for personalized medicine. While ERVEBO itself is not a major revenue generator compared to other biologics, its development and approval have contributed to the overall growth of the biological drugs market, which was valued at USD 296.2 billion in 2023 and is expected to grow to USD 326.12 billion by 2030[3].

Competitive Landscape

In the competitive landscape of biological drugs, ERVEBO stands out as a pioneering vaccine. However, the market is dominated by other biologics, such as monoclonal antibodies and therapeutic proteins, which are used in oncology, autoimmune disorders, and other therapeutic areas. Companies like Merck, Roche, and AbbVie are key players in this market, with significant investments in research and development[3].

Regional Insights

The biological drugs market, including vaccines like ERVEBO, is geographically diverse but heavily concentrated in North America and Europe. These regions have well-developed pharmaceutical industries, advanced healthcare facilities, and streamlined regulatory frameworks, which facilitate the development and market entry of new biologics. The Asia-Pacific region is also experiencing rapid growth, driven by increasing healthcare infrastructure and regulatory approvals[3].

Key Takeaways

  • Development Challenges: ERVEBO's development was marked by a 20-year journey, highlighting the challenges of market failure for neglected tropical diseases.
  • Government Support: Significant government funding and contracts were crucial for the vaccine's development and deployment.
  • Regulatory Approvals: FDA approval and WHO prequalification were pivotal for ERVEBO's global acceptance and use.
  • Market Demand: Demand is driven by public health needs, particularly in regions prone to Ebola outbreaks.
  • Financial Trajectory: ERVEBO contributes to the broader growth of the biological drugs market, which is expected to reach USD 326.12 billion by 2030.
  • Competitive Landscape: The vaccine is part of a competitive market dominated by other biologics, with key players investing heavily in research and development.

FAQs

What was the primary challenge in developing ERVEBO?

The primary challenge was the market failure for neglected tropical diseases, as Ebola is not commercially appealing due to its prevalence in developing countries[1].

How did government funding impact ERVEBO's development?

Government funding, particularly for bioterrorism contracts, was a significant motivator and financial support for the companies involved in the vaccine's development[1].

What regulatory approvals did ERVEBO receive?

ERVEBO was approved by the FDA in December 2019 and received prequalification status from the WHO in November 2019[2][4].

How much funding has the U.S. provided for Ebola response efforts?

The U.S. has provided over $266 million since August 2018 for Ebola response activities in the DRC and surrounding countries[2].

What is the projected growth of the biological drugs market?

The biological drugs market is expected to grow from USD 296.2 billion in 2023 to USD 326.12 billion by 2030, representing a CAGR of 10.1%[3].

Sources

  1. The Ebola Vaccine: A Cautionary Tale - BioSpace
  2. The Current Ebola Outbreak and the U.S. Role: An Explainer - KFF
  3. Biological Drugs Market: Global Industry Analysis - Maximize Market Research
  4. ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP live)] - Merck.com

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.